Exocrine Pancreatic Insufficiency Therapeutics and Diagnostics Market Is Projected to Reach US $6,414.4 Million by 2025
The presence of a handful of companies in the global market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics has rendered the vendor landscape largely consolidated and mildly competitive, observes Transparency Market Research in a new report. Companies contributing to the global EPI therapeutics and diagnostics market are mostly concentrated in Europe and North America.
View full press release